Biomerica, Inc. (BMRA) Stock Score, Valuation & Financial Research
Biomerica, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for BMRA
Biomerica, Inc. currently has a Wall Street Score of 15/100. The stored market price is $2.24. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is -0.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Biomerica, Inc. does
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a
BMRA financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $2.24
- Market capitalization:
- $6.9M
- Revenue:
- $4.5M
- Net income:
- $-3.8M
- Free cash flow:
- $-3.4M
- Cash:
- $1.3M
- Total debt:
- $1.9M
- EPS:
- -1.26
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 6/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-3.4M, showing cash burn in the current stored period.
- The balance sheet shows $1.3M of cash versus $1.9M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.7 points: BMRA decreased 0.7 points because Asset declined by 2.5 points, Capital declined by 2 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BMRA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.